摘要
目的观察得力生注射液肝动脉灌注配合化疗治疗结肠癌肝转移的临床疗效。方法将64例结肠癌术后肝转移患者随机分为治疗组与对照组,每组32例。对照组予XELIRI方案(伊立替康+卡培他滨)化疗,治疗组在对照组基础上加用得力生注射液肝动脉灌注。两组疗程均为3个月,观察临床疗效,比较生存质量(KPS)积分、血液毒副反应(白细胞计数及分级)及免疫相关指标的变化情况。结果 1治疗组、对照组总有效率分别为68.75%和43.75%,组间临床疗效比较,差异有统计学意义(P<0.05)。2治疗组、对照组生存质量积分提高率分别为62.50%、37.50%,两组生存质量变化情况比较,差异有统计学意义(P<0.05)。3治疗前后组内比较,治疗组白细胞计数差异无统计学意义(P>0.05),而对照组差异有统计学意义(P<0.05)。组间治疗后比较,白细胞计数差异有统计学意义,治疗组多于对照组(P<0.05)。同时,两组治疗后白细胞分级水平,差异有统计学意义(P<0.05)。4治疗前后组内比较,治疗组各免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+)差异无统计学意义(P>0.05),而对照组差异有统计学意义(P<0.05);组间治疗后比较,各免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+)差异有统计学意义,治疗组优于对照组(P<0.05)。结论得力生注射液肝动脉灌注配合化疗治疗结肠癌肝转移临床疗效较好,可改善患者的生存质量,减轻化疗的血液毒性,保护机体的免疫功能,为化疗起到增效减毒作用。
Objectlve To obse^e the clinical efficacy of ＂Delisheng Injection＂ by hepatic artery perfusion and chemotherapy in treating liver metastases of colon cancer. Methods Sixty-four cases with liver metastases of colon cancer were randomized into treatment group and control group, with 32 cases in each group. Control group was treated by XELIRI chemotherapy regimens （Irinotecan ＋ apecitabine）, and treatment group was treated by ＂Delisheng Injection＂ additionally, with the course of 3 months. The clinical efficacy, KPS, blood toxicity, immune indicators were observed. Results （1） The overall effective rate was 68.75% in the treatment group and 43.75% in the control group, with a difference between the two groups （P 〈 0.05 ）. （2） The increase rate of KPS score was 62.50% in the treatment group and and 37.50% in the control group, with a difference between the twogroups （ P 〈 0.05 ）. （3） No significant difference was found in WBC of the treatment group （ P 〉 0.05 ）, but there was significant difference in the control group （ P 〈 0.05 ）. After treatment, there was significant difference in WBC and classification of white cells between the two groups （ P 〈 0.05 ）. （4） After treatment, no significant difference was found in the levels of CD3^＋、CD4^＋、CD8^＋、CD4^＋/CD8^＋ in the treatment group （P 〉0.05 ）, but there were significant differences in the control group （ P 〈0.05 ） ; after treatment, significant differences were found in the levels of CD3^＋、CD4^＋、CD8^＋、CD4^＋/CD8^＋ between the two groups （ P 〈 0.05 ）. Conclusion Combined ＂ Delisheng Injection＂ and chemotherapy has better clinical curative effect on liver metastases of colon cancer. It can improve the patient＇ s survival quality, reduce the blood toxicity of chemotherapy, protect the body＇ s immune function, enhance therapeutic effect and reduce toxicity.
出处
《上海中医药杂志》
2014年第11期27-29,共3页
Shanghai Journal of Traditional Chinese Medicine
关键词
结肠癌
肝转移
得力生注射液
肝动脉灌注
化学疗法
减毒增效
colon cancer
liver metastases
＂Delisheng Injection＂
hepatic artery perfusion
chemotherapy toxicity reducing and efficacy enhancing
